Core Viewpoint - Kangyuan Pharmaceutical has initiated clinical trials for Longqi Capsules in accordance with supplementary material requirements and will disclose key information as per legal obligations [1] Group 1: Company Developments - The company is actively contributing to the macroeconomic strategy addressing population aging, focusing on traditional Chinese medicine [1] - Kangyuan has core products targeting health needs of the elderly, including treatments for cardiovascular diseases and bone injuries, such as Ginkgo Biloba Diterpene Injection and Tian Shu Capsules [1] - The company is also developing treatments for Alzheimer's disease, sleep disorders, and chronic obstructive pulmonary disease, with related products entering clinical stages [1] Group 2: Financial Performance - For the period from January to September 2025, Kangyuan Pharmaceutical reported revenue of 2.343 billion yuan, a year-on-year decrease of 24.59% (adjusted) [1] - The net profit attributable to the parent company was 200 million yuan, reflecting a year-on-year decline of 35.63% [1]

Core Viewpoint - Kangyuan Pharmaceutical has initiated clinical trials for Longqi Capsules in response to supplementary material requirements and will disclose key information regarding trial progress and review results in accordance with legal regulations [1] Group 1: Company Initiatives - The company is actively aligning with the macroeconomic strategy of an aging population, leveraging its strengths in traditional Chinese medicine to address health needs of the elderly [1] - Kangyuan Pharmaceutical has core products targeting age-related diseases, including Ginkgo Biloba Diterpene Injection, Tienshu Capsules/Tablets, and Tongsemai Capsules/Tablets [1] Group 2: Research and Development Focus - The company is expanding its research and development efforts in areas related to aging, including Alzheimer's disease, sleep disorders, and chronic obstructive pulmonary disease, with relevant products already in clinical stages [1]